louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07014397: Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth
Official title: Effect of Oral Valaciclovir on Inter- Appointment Endodontic Pain in Single-Rooted Necrotic Teeth With Symptomatic Apical Periodontitis: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Symptomatic Apical Periodontitis
Keywords: symptomatic apical periodontitis (SAP)
herpes viruse
pain
valacyclovir
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
First posted: 2025-06-11
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Aim: To investigate the effect of oral valacyclovir on inter-appointment endodontic pain in single-rooted necrotic teeth diagnosed with symptomatic apical periodontitis (SAP).

Materials and Methods: This study was a randomized, triple-blind, placebo-controlled clinical trial conducted on 38 teeth. Participants were assigned to intervention or control groups using stratified randomization based on gender and baseline pain severity. Both groups received similar root canal treatment; the only difference was the administration of valacyclovir in the intervention group and placebo in the control group. Patients' pain levels were monitored and recorded at 6, 24, and 48 hours post-treatment using a Visual Analog Scale (VAS), along with their consumption of analgesic (ibuprofen).


Eligibility criteria: Inclusion Criteria:

* Patients between 18 and 60 years of age
* Require primary root canal treatment (RCT) in single-rooted maxillary or mandibular teeth (anterior or posterior)
* Diagnosed with symptomatic apical periodontitis (SAP) with confirmed pulp necrosis

Exclusion Criteria:

* Teeth with unrestorable crowns
* Presence of endodontic-periodontal or pure endodontic lesions
* Complex root canal anatomies as defined by the AAE Endodontic Case Difficulty Assessment Form
* Internal or external root resorption
* Calcified canals
* Root canal configuration other than Vertucci's Type I
* Pain originating from more than one tooth
* Marginal periodontitis
* Parafunctional habits
* Systemic diseases classified as ASA class II or higher
* Diagnosed migraine or other headache disorders mimicking orofacial pain
* Intellectual or cognitive impairments
* Pregnancy or breastfeeding
* Use of medications affecting pain perception
* Current use of antibiotics or antiviral agents
* Known allergies to study medications

Primary outcomes:
measure: Pain intensity measured by Visual Analog Scale (VAS)
timeFrame: 6, 24, and 48 hours post-treatment
Secondary outcomes:
measure: Proportion of participants requiring ibuprofen as rescue analgesic
timeFrame: Within 48 hours post-treatment
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Tehran University of Medical Sciences, School of Dentistry
Study officials:
affiliation: Tehran University of Medical Sciences
name: Adnaninia, DDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04804397: Effects of Sucrose Added Blind to the Diet Over Eight Weeks on Body Mass and Weight in Men
Official title: Effects of Sucrose Added Blind to the Diet Over Eight Weeks on Body Mass and Weight in Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight
Keywords: Sucrose
Sugar
Carbohydrate
Weight gain
men
Lead sponsor: University of Hull
Sponsor class: OTHER
First posted: 2021-03-18
Enrollment: 80
Sex: MALE
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Background: Sugar intake, especially in liquid, correlates with obesity. Yet, whether it is a special cause of obesity is less clear. Few experimental studies exist.

Aim: To replicate the investigators' previous 4 week experiments on women with men over 8 weeks to ascertain if: they gain weight given sucrose soft drinks; mood is affected; energy intake is affected.

Participants: 80 men BMI 25-35, aged 30-55. Procedure: After a week of baseline, over eight weeks single blind 40 men received soft drinks containing sucrose (1650 KJ, 97g carbohydrate per day), 40 received control drinks. A three-day food diary with mood ratings and activity levels was completed during baseline and weeks 1, 4 and 8 of the experiment. Body mass was recorded weekly with other anthropometric measures.


Eligibility criteria: Inclusion Criteria:

* BMI 25-35

Exclusion Criteria:

* Diabetes,
* other health problems,
* medication,
* dislike of soft drinks

Primary outcomes:
measure: Body Mass
timeFrame: Eight Weeks
Secondary outcomes:
measure: Daily energy intake assessed by free-living unweighed food diary
timeFrame: Eight Weeks
measure: Mood assessed using 10 rating scales
timeFrame: Eight Weeks
Other outcomes:
Locations:
Study officials:
affiliation: University of Hull
name: Richard Hammersley, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04622397: Local Subfascial and Intramuscular Tranexamic Acid Administration in Pediatric Patient Undergoing Scoliosis Surgery, Double Blind Randomized Control Trial
Official title: Local Subfascial and Intramuscular Tranexamic Acid Administration in Pediatric Patient Undergoing Scoliosis Surgery, Double Blind Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Blood Loss, Surgical
Scoliosis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-11-10
Enrollment: 30
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized comparative study
Primary purpose: PREVENTION

Brief summary: We hypothesized that local administration of tranexamic acid will minimize blood loss and blood product administration in pediatric patient undergoing scoliosis surgery

Detailed description: Spine surgery in paediatrics is frequently associated with substantial blood loss.

Blood product adminestration in children has many complications that are not fully known.

There are many modalities currently available to reduce blood loss in pediatric patients.

Tranexamic acid is tissue plasminogen activator inhibitor that reduce perioperative blood loss.

To date, no studies have investigated effect of local administration of tranexamic acid in pediatric population undergoing scoliosis surgery.

Eligibility criteria: Inclusion Criteria:

* Children aged 2-12 years
* Of both sexes
* American society of anesthesiologist (ASA) physical status classification class I
* Undergoing general anesthesia for scoliosis surgery

Exclusion Criteria:

* Parents' refusal of regional block
* Known allergy to tranexamic acid
* Bleeding disorders (INR \>1.4,Platelet count\< 75000)

Primary outcomes:
measure: Intraperative blood loss in both groups
timeFrame: period of surgery(1-2 hours)
Secondary outcomes:
measure: post-operative blood loss
timeFrame: 24 hours
measure: Blood product admenestration
timeFrame: duration of procedure(1-2 hours)
Other outcomes:
Locations:
Study officials:
References:
citation: Bible JE, Mirza M, Knaub MA. Blood-loss Management in Spine Surgery. J Am Acad Orthop Surg. 2018 Jan 15;26(2):35-44. doi: 10.5435/JAAOS-D-16-00184.
citation: Goobie SM. A blood transfusion can save a child's life or threaten it. Paediatr Anaesth. 2015 Dec;25(12):1182-3. doi: 10.1111/pan.12816. No abstract available.
citation: Mikhail C, Pennington Z, Arnold PM, Brodke DS, Chapman JR, Chutkan N, Daubs MD, DeVine JG, Fehlings MG, Gelb DE, Ghobrial GM, Harrop JS, Hoelscher C, Jiang F, Knightly JJ, Kwon BK, Mroz TE, Nassr A, Riew KD, Sekhon LH, Smith JS, Traynelis VC, Wang JC, Weber MH, Wilson JR, Witiw CD, Sciubba DM, Cho SK. Minimizing Blood Loss in Spine Surgery. Global Spine J. 2020 Jan;10(1 Suppl):71S-83S. doi: 10.1177/2192568219868475. Epub 2020 Jan 6.
citation: Slaughter TF, Greenberg CS. Antifibrinolytic drugs and perioperative hemostasis. Am J Hematol. 1997 Sep;56(1):32-6. doi: 10.1002/(sici)1096-8652(199709)56:13.0.co;2-3.
Clinical trial NCT00723697: Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
Official title: Etude Observationnelle Prospective de l'Utilisation en Situation Reelle; Prospective Real Situation Observational Study of Subutex® or Its Buprenorphine High Dose Generic (BHD) in the Replacement Treatment of Major Opiate Dependence: Following Parameters With Respect to Misuse and Pharmacovigilance
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Buprenorphine
Naloxone
Opiate-related Disorders
Opiate Dependence
Drug Abuse
Keywords: Subutex
Lead sponsor: Indivior Inc.
Sponsor class: INDUSTRY
First posted: 2008-07-29
Enrollment: 1307
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients addicted to opiates and requiring replacement treatment with Subutex (Schering-Plough) or BHD generic (Arrow laboratories)

Brief summary: The purpose of this study is to assess the risks of abuse, misuse and adverse events related to high dose buprenorphine. Approximately 1250 patients taking Subutex (Schering-Plough) or its Buprenorphine High Dose (BHD) generic (Arrow Laboratories) will participate in this study. Data will be collected using physician questionnaires and self evaluation patient questionnaires at the first visit and visits at 6 and 12 months.

Detailed description: Approximately 380 physicians will participate in this study. Patients will be enrolled in chronological order of consultations.

Eligibility criteria: Inclusion Criteria:

* Eligible patients will be those already having a prescription for Subutex or its BHD generic, or being proposed a prescription for Subutex or its BHD generic for the first time when consulting the participating physician.
* The patient must have been informed orally and in writing via the information notice and have signed it.

Exclusion Criteria:

* Criteria of non-eligibility will be related to the contraindications in the Marketing Authorization (MA) of Subutex or its BHD generic

Primary outcomes:
measure: Number of Patients Reporting Misuse (Injection, Sniffing, Dose Fractionation, Modification of Prescribed Doses, and Combination With Psychotropic Agents)
timeFrame: first visit, 6 months, and 12 months
measure: Number of Patients With Misuse (Injection, Sniffing, Dose Fractionation, Modification of Prescribed Doses, and Combination With Psychotropic Agents) as Reported by Physician.
timeFrame: first visit, 6 months, and 12 months
Secondary outcomes:
measure: Number of Patients Reporting Clinical Consequences of Engaging in Misuse
timeFrame: first visit, 6 months, and 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06179797: Chronic Remote Ischemic Conditioning in Vascular Cognitive Impairment: A Dose Escalation Study
Official title: Chronic Remote Ischemic Conditioning in Vascular Cognitive Impairment: A Dose Escalation Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Age-related Cerebral White Matter Changes
Cognition Disorder
Lead sponsor: Augusta University
Sponsor class: OTHER
Collaborators: name: Georgia Rehabilitation Institute
First posted: 2023-12-22
Enrollment: 40
Sex: ALL
Minimum age (years): 56
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized
Primary purpose: TREATMENT

Brief summary: To evaluate the dose-response of relevant blood biomarkers to remote ischemic conditioning in patients with age-related cerebral white matter hyperintensities on MRI, in preparation for a subsequent larger efficacy trial.

Detailed description: Objective: The objective of this early phase study is to evaluate the dose-response of relevant blood biomarkers to remote ischemic conditioning in preparation for a subsequent larger efficacy trial. In addition, we will evaluate the tolerability and adherence to the treatment protocol.

Aim: We aim to measure blood biomarkers in response to daily remote ischemic conditioning (RIC) using a dose escalation study design in 40 patients with age-related cerebral white matter hyperintensities on MRI.

Hypothesis: We hypothesize that there will be a significant change in the biomarker levels in a dose dependent fashion.

Eligibility criteria: Inclusion Criteria:

1. Age ≥55 years
2. Head MRI in the past 6 months showing no more than moderate age related cerebral white matter changes (Fazekas score 0-2).
3. Able to walk without assistance \& independently perform basic activities of daily living.
4. Able to understand this study and agree for a valid consent.

Exclusion Criteria:

Prior non-lacunar (cortical) stroke. 2. Unable to cooperate with the use of the conditioning device. 3. Confounding illness that might interfere with the interpretation of results (such as active malignancy or multiple sclerosis).

4. Contraindication to transient arm ischemia in either arm (such as symptomatic peripheral artery disease).

Primary outcomes:
measure: RBC deformability index
timeFrame: 5 weeks total study duration
Secondary outcomes:
measure: inflammatory and anti-inflammatory Interleukins
timeFrame: 5 weeks
measure: tolerability
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Augusta
country: United States
facility: Wellstar MCG Health
state: Georgia
Study officials:
affiliation: Wellstar MCG Health
name: Carol Smith, RN
role: STUDY_DIRECTOR
References:
Clinical trial NCT01365897: Effectiveness of Modafinil in Improving Cognitive Performance of University Students
Official title: Effectiveness of Modafinil in Improving Mnesic Performance and Executive Functions of University Students From Careers of High Academic Performance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Attention
Memory, Short-Term
Executive Function
Keywords: Modafinil
Memory
Executive Functions
Memory, Short-Term
Attention
University Students
Stroop Effect
Digit Span
Backwards Digit Span
Biber Cognitive Estimation Test
Lead sponsor: Universidad de Valparaiso
Sponsor class: OTHER
First posted: 2011-06-03
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether modafinil is effective in the improvement of mnesic performance and executive functions of university students from high academic performance.


Eligibility criteria: Inclusion Criteria:

* Medicine, Psychology, Obstetrics, Nursing and Kinesiology students of the Universidad de Valparaiso.

Exclusion Criteria:

* Patients with Mental Disorders.
* Patients with physical diseases.
* Patients using any psychotropic substances.
* History of chronic diseases.
* Pregnant women.

Primary outcomes:
measure: Average Correct Answers in Biber Cognitive Estimation Test
timeFrame: 2 hours after pill ingestion
measure: Average response latency in Stroop Effect test
timeFrame: 2 hours after pill ingestion
measure: Average Score in Digit Span test
timeFrame: 2 hours after pill ingestion
measure: Average Score in Backwards Digit Span test
timeFrame: 2 hours after pill ingestion
measure: Average percentage of correct answers in Stroop Effect test
timeFrame: 2 hours after pill ingestion
Secondary outcomes:
Other outcomes:
Locations:
city: Valparaiso
country: Chile
facility: Escuela de Medicina, Universidad de Valparaiso
state: V Region
city: Valparaiso
country: Chile
facility: Escuela de Psicología, Universidad de Valparaiso
state: V Region
Study officials:
affiliation: Universidad de Valparaiso
name: Alejandro Fernández, Psychologist
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidad de Valparaiso
name: Eva Madrid, PhD
role: STUDY_DIRECTOR
affiliation: Universidad de Valparaiso
name: Andrés Painel, BM BCh
role: STUDY_DIRECTOR
affiliation: Universidad de Valparaiso
name: Jonathan Norambuena, BM BCh
role: STUDY_DIRECTOR
affiliation: Universidad de Valparaiso
name: Franco Mascayano, Psychologist
role: STUDY_DIRECTOR
affiliation: Universidad de Valparaiso
name: Walter Lips, Psychiatrist
role: STUDY_DIRECTOR
affiliation: Universidad de Valparaiso
name: Ortega Alonso, Psychologist
role: STUDY_DIRECTOR
References:
Clinical trial NCT02379897: Diet, Obesity and Cardiovascular Risk Study
Official title: Diet, Obesity and Cardiovascular Risk Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Diseases
Obesity
Lead sponsor: Tufts University
Sponsor class: OTHER
First posted: 2015-03-05
Enrollment: 107
Sex: ALL
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Controversy exists about the role of dietary glycemic index (GI) and fat content and cardiovascular risk. Our aim was to assess the long term effects of altering dietary GI, carbohydrate, and fat on body weight, lipids, glucose homeostasis, and C reactive protein (CRP) in overweight and obese subjects. Men and post-menopausal women with body mass index values between 28-38 kg/m2 were placed on an isoweight average American diet for 5 weeks, then randomized to one of 4 diets which differed in GI, carbohydrate and fat content with calorie restriction for 12 weeks. The same diets were continued for 5 weeks under isoweight conditions, and in the free-living state for 48 weeks.


Eligibility criteria: Inclusion Criteria:

* BMI 28-28 kg/m2
* Male or postmenopausal female 45-65 yr

Exclusion Criteria:

* Abnormal thyroid, liver, kidney function
* Abnormal hemoglobin
* LDL-cholesterol ≤ 100 mg/dL
* Fasting triglycerides ≥ 400 mg/dL
* Diabetes or on medication for diabetes
* Chronic illness
* Elevated blood lipids

Primary outcomes:
measure: Change in body weight
timeFrame: Baseline to 12 weeks
Secondary outcomes:
measure: Change in fasting plasma high density lipoprotein cholesterol
timeFrame: Baseline to 12 weeks, 17 weeks, and 16 months
measure: Change in fasting plasma low density lipoprotein cholesterol-cholesterol
timeFrame: Baseline to 12 weeks, 17 weeks, and 16 months
measure: Change in fasting plasma very low density lipoprotein cholesterol-cholesterol
timeFrame: Baseline to 12 weeks, 17 weeks, and 16 months
measure: Change in fasting plasma triglycerides
timeFrame: Baseline to 12 weeks, 17 weeks, and 16 months
measure: Change in fasting plasma insulin
timeFrame: Baseline to 12 weeks, 17 weeks, and 16 months
measure: Change in fasting blood glucose
timeFrame: Baseline to 12 weeks, 17 weeks, and 16 months
measure: Change in glycated hemoglobin
timeFrame: Baseline to 12 weeks, 17 weeks, and 16 months
measure: Change in plasma C-reactive protein
timeFrame: Baseline to 12 weeks, 17 weeks, and 16 months
measure: Change in body fat
timeFrame: Baseline to 12 weeks and 17 weeks
measure: Change in resting metabolic rate
timeFrame: Baseline to 12 weeks and 17 weeks
measure: Change in blood pressure
timeFrame: Baseline to 12weeks, 17weeks and 16months
measure: Change in body weight
timeFrame: Baseline to 17weeks and 16months
measure: Change in postprandial blood glucose
timeFrame: Baseline to 12weeks and 17weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01250197: Formulation Comparison in Normal Volunteers
Official title: A Double-masked, Crossover Study Assessing the Ocular and Systemic Safety and Systemic Absorption of Two Formulations of 0.5% AR-12286 Ophthalmic Solution in Normal Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Normal Volunteers
Keywords: Normal Volunteers
Lead sponsor: Aerie Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2010-11-30
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a double-masked, single-center, crossover study in which normal volunteers will be randomized to receive one of two formulations of 0.5% AR-12286 Ophthalmic Solution for 8 days. Subjects will undergo a minimum 7-day washout, and then receive the alternate treatment for 8 days.

Detailed description: Not desired.

Eligibility criteria: Inclusion Criteria:

* Normal volunteers

Exclusion Criteria:

* Active ophthalmic or systemic disease

Primary outcomes:
measure: Ocular safety
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Celerion
state: Arizona
Study officials:
affiliation: Aerie Pharmaceuticals, Inc.
name: Tom van Haarlem, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03416205: A Prospective Study of Treating Duodenal Papillary Sphincter in Different Ways During ERCP
Official title: A Prospective Study of Treating Duodenal Papillary Sphincter in Different Ways During ERCP: Comparison of EST, EPBD, and sEST+EPBD in Endoscopic Choledocholithiasis Treatment.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: ERCP
Lead sponsor: Zhujiang Hospital
Sponsor class: OTHER
Collaborators: name: Nanfang Hospital, Southern Medical University
First posted: 2018-01-31
Enrollment: 450
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Endoscopic retrograde cholangiopancreatography (ERCP) is commonly performed to remove bile duct stones.Endoscopic sphincterotomy (EST), endoscopic papillary balloon dilation (EPBD), and endoscopic sphincterotomy plus balloon dilation (sEST+EPBD) are 3 methods used to enlarge the papillary orifice, but their efficacy and safety remains controversial. This study aimed to compare these methods for treating common bile duct (CBD) stones.

Detailed description: Investigators first divided the patients with different sizes of common bile duct stones into two groups. The bile duct stone diameter of group A is less than 1.0cm while group B is more than 1.0cm and less than 1.5cm. Each group compared Endoscopic sphincterotomy (EST), endoscopic papillary balloon dilation (EPBD), and endoscopic sphincterotomy plus balloon dilation (sEST+EPBD) in ERCP. Through the postoperative comparison of relevant inspection test indicators, the recovery of patients, whether the occurrence of complications, including infection,bleeding,pancreatitis,perforation , and 1 year stone recurrence rate,Investigators assess the advantages and disadvantages in three different strategies in different sizes of common bile duct stones , and finally get a relatively objective evaluation to guide our daily ERCP work on the choice of duodenal papillary sphincter treatment strategy.

Eligibility criteria: Inclusion Criteria:

* Age 20-80 years old
* CT or MRCP diagnose the patients with Common bile duct stones
* The diameter of the stone is less than or equal to 1.5cm
* Patients with the indications for ERCP
* Patients and their families agree to participate in the trial

Exclusion Criteria:

* Stones are too large (\> 1.5cm)
* A history of gastrointestinal surgery
* ERCP and EST or EPBD surgery history
* Patients generally poor, total bilirubin\> 200umol / L or PT time extension\> 3s
* Patients with mental illness or other serious heart and lung disease

Primary outcomes:
measure: the incidence of composite events of infection, hemorrhage, perforation, pancreatitis
timeFrame: 3 and 24 hours after the ERCP
Secondary outcomes:
measure: Recurrence rate of bile duct stones
timeFrame: 1 year after the ERCP.
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhujiang Hospital
state: Guangdong
Study officials:
affiliation: Zhujiang Hospital
name: Changhui Yu, Doctor
role: PRINCIPAL_INVESTIGATOR
References: